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Abstract 
 
The application of rhenium complexes as therapeutic agents in nuclear medicine has propelled 
research into the chemistry of these compounds. In our effort to develop and investigate new 
therapeutic radiopharmaceuticals based on the complexes of rhenium we have investigated the 
nitride core, [ReN]2+. This work looks at the behavior of sulfonamide based dithiocarbimates 
towards the rhenium(V) nitride core. The aim here was to prepare anionic complexes with 
aromatic as well as fluorescent aromatic groups in the sulfonamide substituent located on the 
dithiocarbimate backbone. We envisaged that the polar sulfonamide and dianionic charge 
would confer solubility in water. Here we report the reactions of the dithiocarbimate ligands 
towards the rhenium(V) precursors: [ReNCl2(PPh3)2] and [ReNCl2(PMe2Ph)3]. These reactions 
proceeded with bis-substitution by the dithiocarbimate ligand, resulting in the formation of a 
dianionic rhenium(V) complex, of the type [ReN(S-S)2]
2−, where (S-S) denotes the 
sulfonamide-tagged dithiocarbimato unit. Spectroscopic characterization data, as well as the 
synchrotron X-ray diffraction structure of the metal complex with the phenyl sulfonamide 
backbone shed light into the structural features of this interesting class of ligands and opens up 
opportunities for further studies in molecular imaging and therapeutic arenas 
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Introduction 
 
Despite significant progress made in the development of diagnostic radioisotopes for medical 
imaging techniques such as single photon emitted computed tomography (SPECT) or positron 
emission tomography (PET), the availability of therapeutic radioisotopes with matching 
radiochemistry, half-lives and wide accessibility at reasonable costs remains the holy-grail for 
applications in nuclear medicine, particularly for oncology. The development of rhenium 
compounds as therapeutic radiopharmaceuticals remains a matter of interest for chemists and 
nuclear imaging specialists both in academic and in clinical settings. 
To date, the most widespread use of rhenium complexes in major clinical applications is that 
involving ReHEDP (hydroxyethane bisphosphonate) for uses in bone targeting in terminal 
cancer patients [1]. The research area has been reviewed: the chapters in Comprehensive 
Coordination Chemistry on Technetium by Alberto [2] and Rhenium by Abram, [3] are 
detailed. Extensive reviews have covered the recent chemistry aspects of both 186/188Re 
and 99mTc chemistry across a whole range of available oxidation states and coordination 
numbers in aqueous and non-aqueous media [4,5]. Our recent book Chapter also gives an 
overview of the development of the coordination chemistry of Tc and Re relevant to nuclear 
medicine with an emphasis on key ligand systems and imaging agents [4]. 
 
The strong π-donating characteristics of the trianionic nitride-group make a major contribution 
to the stability of high oxidation state Tc and Re nitrides. The presence of an additional negative 
charge on “nitride” compared to “oxo” opens up a series of complexes with different co-
ligands, or overall charges, to those of the ubiquitous Re-oxo complexes. Tc or Re nitride 
syntheses were first carried out by Chatt et al. who showed that [ReNCl2(PPh3)2] and 
[ReNCl2(PMe2Ph)3] could be synthesized using hydrazine or azide as the source of 
nitride [6,7]. This work was extended to 99Tc and 99mTc: Baldas and co-workers reported 
extensively on nitride complexes and proposed that the nitride core could be used in 99mTc 
based radiopharmaceuticals [8–14]. The paramagnetic Tc(VI) species [TcNCl4]− emerges from 
the reaction between pertechnetate and azide in acid solution. Its substitution and redox 
chemistry (by the same synthetic route) was applied to the synthesis of [ReNCl4]
−[15]. The 
coordination chemistries and spectroscopic properties of the [TcN]2+ and [ReN]2+ cores were 
highlighted by Abram et al. and some representative examples of this work are shown 
in Fig. 1 (A–C) [16–18,15,19]. In the nitride complexes research space, Duatti and co-workers 
showed that neutral dithiocarbamato-Tc nitrides act as promising heart imaging agents. 
Particularly, the bis(N-ethoxy, N-ethyl dithiocarbamato)nitrido technetium(V), TcNOET (Fig. 
1, compound D) entered clinical trials despite the fact that myocardial tissue retention remains 
unclear [20–22]. 
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Figure 1. Representative examples of complexes exhibiting the TcN and ReN cores. 
 
The hydrazine derivative MeSCSNMeNH2 and its variants led to the formation of both 
[TcN]2+ and [ReN]2+ cores directly from the corresponding tetroxometallates in high 
yields [23,24]. No intermediates could be isolated with the Tc core but the 
[ReO(NHNMeCSSMe)2]
+ species emerged from the reaction of [ReO4]
− with the N-
methylated hydrazine in the presence of HCl, followed by addition of a dithiocarbimate (dtc) 
to give [ReN(dtc)2] [25]. To incorporate the nitride core, it is of interest to synthesize 
complexes with a mixed ligand system analogous to a [3 + 2] systems, which have been shown 
to be effective for oxo complexes. The same approach for the nitrides gives mixtures of 
compounds, however, it has been shown that the stereochemistry and stoichiometry of the Tc 
or Re nitride cores can be controlled using tridentate SNS or PNP donors. In the case of PNP 
ligands, the π-acceptor P donors favor a trans geometry [26]. The halide ligands are placed in 
a cisposition and they can readily be substituted by bidentate monoanionic or dianionic 
ligands [27]. This control level can be achieved with bidentate nitrogen ligands (i.e. bipy, 
phenanthroline) that allow the isolation of the cyanonitrido complexes [28]. The use of bulky 
thiolate ligands demonstrated stabilizing effect on the rhenium nitride, arylimido and nitrile 
cores [29]. 
 
The structure of the Re dichloride (compound E) and the cationic dithiocarbamate derivative 
bis[(dimethoxypropylphosphanyl)ethyl]ethoxyethylamine N,N′-bis(ethoxyethyl) 
dithiocarbamato nitrido technetium(V), Tc-N-DBDOC (compound F which shows promise as 
a cardiac imaging agent in vivo) are shown in Fig. 1[30]. A choice of bidentate ligands with 
bioorthogonal functionalization can lead to conjugation to a range of biomolecules as well as 
hig kinetic stabilities [31–35]. 
 
Rhenium has two beta-emitting radioisotopes, 186Re and 188Re, and through careful ligand 
design these can be encapsulated and then targeted to cancer cells where the beta-radiation 
emitted destroys the cancer cells. Both of these species are reactor-produced radioisotopes 
which are attractive for a variety of therapeutic applications. Thus far, Re-186 is unavailable 
from a generator system, and must therefore be directly produced in a nuclear reactor. 
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However, Re-188 can be eluted as perrhenate from an alumina-based 188W/188Re generator, and 
although it has a much shorter half-life of 16.9 h, this is still compatible with most in 
vivo imaging and therapy requirements as it emits a beta-particle with a much higher energy 
(2.12 MeV and a 155 keV gamma photon, 15%) which would be also suitable for the coupled 
SPECT imaging.  
 
To date, the majority of research into rhenium based therapeutic agents design has centered 
around the rhenium(V) oxo core. Our approach in this study was to investigate the coordination 
of a series of sulfonyl-dithiocarbimate ligands to the rhenium(V) nitride, [Re N]2+ core. This 
work focuses on the synthesis and coordination behavior of sulfonamide based 
dithiocarbimates (Scheme 2, SDTC 1–4) towards the rhenium(V) nitride core. The aim here is 
to functionalize the dithiocarbimate backbone by incorporating both fluorescent and non-
fluorescent aromatic groups in the sulfonamide substituent. This will enable observation of the 
behavior of these complexes at the cellular level. To date, the only related rhenium compounds 
reported in the literature are neutral and involve the diethyldithiocarbamate ligand [36,37]. 
 
A measure of water solubility is a prerequisite for metal complexes to be used in biomedical 
applications. A commonly adopted approach is to add polar groups containing carboxylate, 
hydroxy or sulfonate groups to the ligand backbone. Here, we have adopted an alternate 
approach by using sulfonyl substituted dithiocarbimate ligands. Dithiocarbimate ligands have 
been relatively little studied and there have been just a couple of X-ray structures reported of 
Re complexes, readily prepared from sulfonamides and CS2 in the presence of a base [38,39]. 
They have two possible resonance forms as shown in Scheme 1. In form B, one negative charge 
resides on a sulfonyl oxygen giving a charged group closely related to the sulfonic acids 
(RSO3
−). We anticipate that such complexes could be water-soluble and this would be enhanced 
by a negative charge on the complex.  
 
 
 
Scheme 1. Proposed resonance forms for dithiocarbimate-based ligands. 
 
The substituents on the sulfonyl backbone of the ligands, methyl, phenyl, tolyl and naphthyl 
groups, have been carefully chosen in the work reported hereby to improve kinetic stabilities 
and modulate the lipophilicities. To enhance the understanding of the behavior of these 
compounds in cells across a range of conditions and concentration domains, a fluorescent 
ligand tag (e.g. naphthyl based) is desirable as it would allow the monitoring of the in 
vitro behavior of the compound. The design and synthesis of a series of ligands and of their 
novel complexes are here reported. Currently there are no reports in the literature regarding X-
ray structures of Re complexes with this ligand. New species were characterized in solution 
and in the solid state, and their UV–Vis spectroscopy behavior in solution was investigated. 
The fluorescence spectra of a new naphthyl-tagged ligand and investigations into its 
corresponding Re(V) complex are also reported. A stability study of the tolyl complex, 
[ReN(SDTC2)2]
2−, in the presence of water over a period of 6 h was also conducted showing 
promising kinetic stability compatible with its intended pre-clinical aims. The complex proved 
to be stable in the presence of H2O, with the UV–Vis spectra showing little change over this 
period. 
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Results and Discussions 
 
The synthesis of the sulfonamide dithiocarbimate ligands was adapted from literature 
procedures [36,37] and successfully employed for all starting materials with alkylic and arylic 
backbones. The addition of carbon disulfide to the sulfonamides in a basic medium yielded the 
dianionic dithiocarbimate ligands as potassium salts (Scheme 2). 
 
 
 
Scheme 2. General synthesis for dithiocarbimate ligands. 
 
A significant fluorescence emission was observed for the dianionic ligand with the naphthyl 
backbone (denoted SDTC4) with excitation and emission in the UV region of the spectrum 
(Fig. 1). Interestingly, the excitation and emission spectra also showed peaks of lower intensity 
in the NIR region (650–700 nm). The fluorescence emission in this region is especially 
attractive for biomedical imaging as interference from tissue autofluorescence in vitro and in 
vivosubstantially decreases in the NIR.   
 
 
 
 
Figure 2. Normalized excitation (black line) and emission (orange line) spectra of ligand 
[SDTC4]K2 in CH3CN/H2O. 
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Scheme 3. General procedure for the preparation of [ReN(SDTC)2][PPh4]2 complexes anions. 
The two [PPh4]
+ counterions were omitted in the scheme shown above. 
 
The reaction of the ligands with rhenium nitride precursors results in bis-substitution of the 
dithiocarbimate ligand, and in the formation of a dianionic rhenium(V) complex of the type 
[ReN(SS)2]
2− (Scheme 3). 
 
The desired complexes featuring the [ReN]2+ (Re(V)) core were obtained either from the 
[ReNCl2(PPh3)2] or [ReNCl2(PPhMe2)3] by refluxing in methanol with the ligands and adding 
PPh4Br to generate the counter-ion. The negative ESI TOF mass spectra obtained for the 
[ReN(SDTC3)2]
2− complex show peaks for the protonated complex, [M+H]−, but also for the 
dianionic species, m/z corresponding to [M]2−. The ESI TOF results obtained for the complex 
[ReN(SDTC4)2]
2−, however, only showed the dianionic species [M]2−(see ESI). 
 
 
 
 
Figure 3. A) UV-vis spectra of Re nitride complexes in CH3CN (10 mM conc); B) Stability 
tests of [ReN(SDTC2)2][PPh4]2 by UV-Vis spectroscopy in aqueous CH3CN (ca. 1:1 
CH3CN:H2O, 10 mM). 
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Furthermore, the UV–vis spectra of the prepared rhenium complexes are summarized 
in Fig. 3(A) as well as the corresponding stability test in aqueous media for 
[ReN(SDTC4)2][PPh4]2 is given in Fig. 3(B). The absorption maxima is maintained at ca. 270–
280 nm and in the case of SDTC4, the bands above 300 nm are not observed in the complex. 
 
Interestingly, a search in the literature confirmed that the reported X-ray crystal structures for 
rhenium nitride complexes with bidentate S-donor ligands are scarce (vide infra). Among these, 
only a handful display a square pyramidal geometry like the compounds described herein. 
Other examples including those with additional phosphine ligands and adopting a pseudo-
octahedral geometry [40–42] or multimetallic complexes [43–49] are outside the scope of this 
discussion and consequently not included here. 
 
The closest examples to the complexes prepared in this work are depicted in Fig. 4. In all 
examples, the Re-N nitride distances are practically identical while the Re-S distances vary 
more with the type of ligands. The dithiolate derivative, II[15], presents the shorter Re-S 
distances followed by the complexes containing dithiocarbimate ligands, I[50] and 
[ReN(SDTC1)2][PPh4]2. The longer distances found are consistent with the likely occurrence 
of the canonical form B in Scheme 1. The complex with dithioimidophosphinato 
ligands, IV[19], presents the longest Re-S distances with values around 2.4 Å (Fig. 4). The 
ORTEP representation of the [ReN(SDTC1)2][PPh4]2 complex acquired using synchrotron X-
ray radiation is represented in Fig. 5 and a summary of the most representative structural 
parameters is listed in Table 1. 
 
 
 
 
 
Figure 4. Distances (Å) and angles (italics, º) of ReN complexes including S donor ligands in 
a square pyramidal geometry. Hydrogen atoms have been omitted for clarity. 
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Figure 5. Synchrotron X-ray diffraction data (= 0.69110 Å); molecular structure of 
[ReN(SDTC1)
2
][PPh4]2. Ellipsoids shown at the 50% level. PPh4
+ cations and hydrogen atoms 
have been omitted for clarity.  
 
 
Table 1. Selected bond lengths and angles for the complex [ReN(SDTC1)2][PPh4]2. 
 
Bond Bond length (Å) Angle Bond angles (°) 
Re1-N1 1.655(5) N1-Re1-S1 108.2(2) 
Re1–S1 2.373(1) N1-Re1-S2 108.4(2) 
Re1–S2 2.393(1) N1-Re1-S4 106.1(2) 
Re1-S4 2.368(1) N1-Re1-S5 105.4(2) 
Re1-S5 2.393(1) S1-Re1-S2 72.86(4) 
N2-C1 1.282(6) S4-Re1-S5 72.98(4) 
N3-C8 1.280(6) S2-Re1-S4 145.48(5) 
S1-C1 1.750(5) S1-Re1-S5 146.27(5) 
S2-C1 1.758(4) S1-C1-S2 107.5(3) 
S4-C8 1.754(5) S4-C8-S5 107.2(3) 
S5-C8 1.764(4) C1-N2-S3 121.5(4) 
  C8-N3-S6 121.9(4) 
 
 
Additionally we carried out investigation by DFT calculations on the binding of the anionic 
ligands to the [ReN]2+ core. For the model ligand SDTC1, and the corresponding dianionic 
complex, gas phase DFT optimizations using a variety of basis sets under Gaussian platforms 
were employed. In each case, as expected for these bonding models, there are delocalized 
bonding throughout which appeared to be favored for both the experimental structure and the 
model compounds. The optimized (Fig. 6, Table 2 and ESI) geometries are in agreement with 
the findings from X-ray diffraction studies on [ReN(SDTC1)2][PPh4]2 and other literature 
data [15,19,50] and Figs. 4 and 5. 
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Figure 6. DFT calculated energies and shapes of selected frontier orbitals (HOMO and LUMO) 
for (a) [(SDTC1)]2- and (b) [ReN(SDTC1)2]2-. Additional frontiers orbitals and their energies 
are given in ESI. Structures optimized in the gas phase using the exchange correlation 
functional PBEPBE LANL2TZ/631G** basis set. 
 
 
 
Table 2. DFT Calculated bond lengths and angles for the anion complex [ReN(SDTC1)2]2- 
using the PBEPBE exchange correlation function and two different basis sets. Additional 
conditions surveyed are given in ESI. 
 
Bond 
Bond length (Å) 
Angle 
Bond angles (°) 
LANL2TZ/ 
6-31G** 
aug- cc-PVTZ 
pp/ 6-31G** 
LANL2TZ 
/6-31G** 
aug- cc-
PVTZ pp/ 
6-31G** 
Re1-N1 1.669 1.665 N1-Re1-S1 107.17 107.32 
Re1–S1 2.421 2.411 N1-Re1-S2 106.74 106.95 
Re1–S2 2.426 2.415 N1-Re1-S4 106.88 106.82 
Re1-S4 2.424 2.417 N1-Re1-S5 107.20 107.32 
Re1-S5 2.419 2.412 S1-Re1-S2 72.62 72.65 
N2-C1 1.324 1.325 S4-Re1-S5 72.67 72.63 
N3-C8 1.323 1.325 S2-Re1-S4 146.38 146.24 
S1-C1 1.775 1.774 S1-Re1-S5 145.62 145.35 
S2-C1 1.771 1.769 S1-C1-S2 108.08 107.65 
S4-C8 1.772 1.769 S4-C8-S5 107.94 107.65 
S5-C8 1.776 1.774 C1-N2-S3 123.38 122.80 
 
 
 
HOMO       156.69 kJ/mol LUMO         269.82 kJ/mol 
HOMO      419.63 kJ/mol LUMO       462.96 kJ/mol 
(a) 
(b) 
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Key structural data for the experimental structure, species modelled as well as the partial charge 
distributions estimated are also given in the Supporting Information.  
 
Molecular parameters are in agreement with those resulting from the X-ray structural data and 
the calculated IR spectra [STDC1]2− and [ReN(STDC1)2]
2−also support the assignments made 
for the experimental IR spectra (ESI). The shapes and energies for the frontier orbitals for the 
[STDC1]2− and [ReN(STDC1)2]
2− (DFT-calculated, Fig. 6) are also given. These are of interest 
to explore in the context of the fact that UV–Vis spectroscopy of the Re(V) compound could 
be observed experimentally and showed strong absorption bands in the 250–350 nm region of 
the spectrum. Encouraged by these calculations the involvement of such frontier orbitals in the 
transitions responsible for fluorescence emission spectra was also evaluated. Whilst for the 
simple complexes bearing the [SDTC1]–[SDTC3] anionic ligands the fluorescence was rather 
weak, the fluorescence emission spectrum of the potassium salt of the SDTC4 free ligand was 
observed (Fig. 2 and ESI). Interestingly, the fluorescence emission quenching upon metallation 
with Re(V) and the formation of the [ReN(SDTC4)2]
2− complex dianion occurred in CH3CN 
solutions (ESI). This loss of fluorescence emission may well be as a result of non-radiative 
pathways due to the dynamic equilibria between canonical forms A/B (shown in Scheme 1) of 
the coordinating ligand becoming involved in solutions. Also, the presence of traces of 
paramagnetic rhenium species forming in aerated solution during the analysis could not be fully 
discounted at first, therefore the kinetic stability tests in aqueous environment were carried out: 
spectroscopic evaluations of compounds of this class showed a remarkable kinetic stability in 
water media (Fig. 3B). The complex [ReN(SDTC2)2]
2− proved to be stable in CH3CN:H2O 
with the UV–Vis spectra showing little change over this period. Taking the shape and energies 
of HOMO-LUMO calculated by DFT for SDTC1 and [ReN(SDTC1)2]
2− in the simplified gas 
phase models (using a wide variety of basis sets and conditions, ESI), it is feasible to assume 
that these frontiers orbitals are involved in the observed electronic absorption bands and in the 
occurrence of fluorescence [51]. The higher energy gap between the HOMO and LUMO 
orbitals in the complex compared to the ligand can indicate that the metal-to-ligand charge 
transfer associated to the fluorescence process is not as favored resulting in a quenching of the 
fluorescence intensity. Furthermore, the stability study of the tolyl complex, 
[ReN(SDTC2)2]
2− monitored in an organic solvent (CH3CN) in the presence of water over a 
period of 6 h was also conducted showing promising kinetic stability compatible with its 
intended pre-clinical aims. Longer term we are interested in setting the foundations for the 
Re(V) radiochemistry labelling which requires aqueous conditions. As such, prior to engaging 
in extensive ‘hot’ experiments using 186/188Re we have been establishing the ‘cold’ chemistry 
protocols hereby, and fluorescence spectroscopy proved to be a helpful tool in assessing the 
necessary compatibility and kinetic stability in aqueous solutions. 
 
Conclusions and outlook 
 
The synthesis of new ligands and their [ReN]2+ core-tagged complexes was described herein. 
The characterization data in solution and in the solid state as well as the crystal structure of the 
metal complex [ReN(SDTC1)2](PPh4)2 are given. This compound is representative of the series 
and incorporates the phenyl sulfonamide backbone: its geometry was discussed and compared 
to DFT level gas-phase calculations. Additional highlights are the fact that the free dianionic 
ligand SDTC4 isolated as a potassium salt is fluorescent in wet solvents, however, it is clear 
that quenching has taken place upon its coordination to the Re(V) centre. New coordination 
chemistry of Re(V) in wet organic solvents was developed hereby and opens up the possibility 
of generating complexes including the [S(O)2N] moiety known for playing a role in the 
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selective reductive trapping of related compounds in hypoxic cells and tissues: further work in 
this context is currently in progress in our laboratories. 
 
Experimental Section 
The rhenium precursors [ReNCl2(PPh3)2], and [ReNCl2(PMe2Ph)3] were prepared according to 
literature procedures.[7, 52] These complexes were fully characterized and used in further 
reactions to give the desired metallic sulfonamide based dithiocarbimates. 
 
General procedure for sulfonamide dithiocarbimate synthesis 
Ligands SDTC1 to SDTC4 as dipotassium salts were prepared following literature 
procedures.[37, 38] Generally, carbon disulfide (1 eq.) and KOH (1 eq.) were added to the 
sulfonamide starting material (1 eq.) dissolved in DMF. The reaction was stirred at 0 ºC for 2 
h and a second equivalent of KOH added and the mixture further stirred for 1 h. The removal 
of the solvent resulted in the precipitation of the dithiocarbimate salts as pale yellow solids. 
 
Dipotassium (phenylsulfonyl)carbonimidodithioate (SDTC1): Yield: 51%. Anal. Calc. for 
C7H5S3O2NK2·2H2O: C, 24.3; H, 2.6, N, 4.0%. Found: C, 24.1; H, 2.4; N, 3.9%.
1H NMR (d6-
DMSO): δ 7.28-7.34 (m, 3H); 7.65-7.72 (m, 2H). IR (cm-1): 1263 (CN); 1253 (SO2ass); 1132 
(SO2sym); 978 (CS2). 
Dipotassium (tosyl)carbonimidodithioate (SDTC2): Yield: 94%. Anal. Calc. for 
C8H7S3O2NK2·3H2O: C, 25.4; H, 3.5; N, 3.7%. Found: C, 25.1; H, 2.9; N, 3.7%. 
1H NMR (d6-
DMSO): δ 7.57 (d, J = 8.0 Hz, 2H); 7.06 (d, J = 8.0 Hz, 2H); 2.26 (s, CH3). IR (cm-1): 1267 
(CN); 1256 (SO2ass); 1136 (SO2sym); 973 (CS2). 
Dipotassium (methyl)carbonimidodithioate (SDTC3): Yield: 60%. 1H NMR (d6-DMSO): δ 
2.98 (s, 3H). IR (cm-1): 1287 (CN); 1265 (SO2ass); 1187 (SO2sym); 960 (CS2). 
Dipotassium (naphthylsulfonyl)carbonimidodithioate (SDTC4): Yield 83 %. Anal. Calc. 
for C11H7S3O2NK2·H2O: C, 35.0; H, 2.4; N, 3.7%. Found: C, 34.5; H, 2.6; N, 3.3%. 
1H NMR 
(d6-DMSO): δ 8.40 (s, 1H), 8.15 – 8.04 (m, 2H), 8.01 (d, J = 7.5 Hz, 1H), 7.88 (d, J = 8.6 Hz, 
1H), 7.71 – 7.59 (m, 2H). IR (cm-1): 1273 (CN), 1264 (SO2ass), 1144 (SO2sym), 971 (CS2). 
 
General procedure for the synthesis of sulfonamide dithiocarbimate rhenium nitride 
complexes 
 
ReNCl2(PPh3)2 (0.120 g, 0.151 mmol) was added to [SDTC1]K2  (0.164 g, 0.530 mmol) in 
methanol (50 mL) and the resulting solution was heated under reflux for a period of 4 h. To the 
orange/brown solution obtained, PPh4Br (0.128 g, 0.305 mmol) was added in 3 mL of 
methanol. The solution was filtered, the solvent removed under vacuum, and the residue 
re-dissolved in 25 mL of dichloromethane. This solution was washed with H2O and the organic 
layer dried over MgSO4. The addition of an excess of diethyl ether yielded yellow precipitates, 
which in each case was washed with diethyl ether and dried under vacuum.  
 
[ReN(SDTC4)2](PPh4)2 complex was isolated in a yield lower than 10% and characterized by 
mass spectrometry, IR, UV-Vis and fluorescence spectroscopies.  
[ReN(SDTC1)2](PPh4)2: The complex was prepared following the general procedure from 
ReNCl2(PPh3)2, yield: 45 %. Anal. Calc. for C62H50S6O4P2N3Re: C, 55.5; H, 3.8; N, 3.1. Found: 
C, 55.2; H, 3.8; N, 3.1%. 
Alternatively, this rhenium complex was prepared starting from ReNCl2(PMe2Ph)3 precursor 
and following the same experimental protocol. The same product was obtained. Yield: 90 %. 
Anal. Calc. for C62H50S6O4P2N3Re.H2O: C, 54.8; H, 3.9; N, 3.1%. Found: C, 54.4; H, 3.8; N, 
3.0%. 
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[ReN(SDTC2)2](PPh4)2: The complex was prepared following the general procedure, from 
ReNCl2(PPh3)2, yield: 57 %. From ReNCl2(PMe2Ph)3, yield: 45 %. Anal. Calc. for 
C64H54S6O4P2N3Re: C, 56.1; H, 4.0; N, 3.1. Found: C, 56.3; H, 3.9; N, 2.8%. 
[ReN(SDTC3)2](PPh4)2: The complex was prepared following the general procedure from 
ReNCl2(PPh3)2, yield: 57 %. From ReNCl2(PMe2Ph)3, yield: 45 %. Anal. Calc. for 
C52H46S6O4P2N3Re·4H2O: C, 48.4; H, 4.2; N, 3.3; S, 14.9%. Found: C, 48.1; H, 3.9; N, 3.6; S, 
15.2%. 
 
Crystal Structure Determination 
Crystals suitable for X-ray crystallography were obtained from the slow evaporation of a 
methanol solution of the complex at room temperature. The crystals were isolated by filtration, 
and a specimen crystal was selected under an inert atmosphere, covered with polyfluoroether 
and mounted on the end of a glass fibre.  
 
Crystallographic data for [ReN(SDTC1)2](PPh4)2 were collected at the SRS Daresbury 
Radiation Source. The crystal structure was deposited at the Cambridge Crystallographic Data 
Centre.  The data have been assigned to the deposition numbers: CCDC 1561939 contains the 
supplementary crystallographic data for this paper. These data can be obtained free of charge 
from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. 
The asymmetric unit consists of 1.5 Re-complex molecules and three PPh4 cationic species as 
counterions. One generally well-ordered formula unit is 2(C24H20P)(C14H10 N3O4ReS6). The 
Re complex with Re2 atom is located on a centre of inversion, with Re2 and N2 disordered 
over two sites which were refined with 50% occupation. One tosyl-group in the complex with 
Re1 shows disorder over two sites in the ratio 54:46. Three out of four phenyl groups attached 
to P3 are disordered over two sites and were modelled with geometric constraints.  
 
Unit cell Parameters: a= 10.3136(2) Å, b= 14.3596(3) Å, c= 58.1686(14) Å, beta= 
92.0450(10)°, space group P21/n, Z=6, V= 8609.2(3) Å3, T= 150(2) K, µ= 2.158mm
-1
; Formula 
weight 1341.55, 67942 reflections measured (Rint 0.073); Data/restraints/parameters: 22882 / 
12 / 1214. Final R indices [I>2σ(I)]Full-matrix least-squares refinement on F2: R1 = 0.0560 
and wR2 =0.1461. R indices (all data) R1= 0.0733 and wR2 =0.1533. 
 
 
DFT Calculations 
All calculations were carried out using density functional theory with different exchange 
correlation functionals (B3LYP, B3PW91, BVP86, HSEH1PBE, MPW1PW91 and PBEPBE) 
as implemented in the Gaussian 09 package.[54] Different basis sets (SDD, LANL2DZ, 
6311+G*, 631G**, LANL2TZ, aug-cc-PVTZ-pp, Def2 TZVPPD, HAY WADT MBN1ECP 
and dhf TZVPP) were used to get the accurate geometries of  [STDC1]2- and [ReN(STDC1)2]
2- 
closer to the experiment. Calculated bond lengths and bond angles using different combinations 
of exchange correlation functionals and basis sets together with the experimental values are 
given in the electronic supplementary information. All geometry optimizations were performed 
without symmetry constraints. Vibrational frequencies were calculated on the optimized 
structures and were scaled using a scaling factor of 0.986. Mulliken[55] and natural[56] 
population analysis were carried out to estimate the charges on each atoms. Molecular orbital 
diagrams were generated using GaussView 6.0.16 visualization program included in the 
Gaussian 09 package. 
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